ISEE - IVERIC bio, Inc. Stock Price and Quote

ISEE [NASD]

Index	-	P/E	-	EPS (ttm)	-1.52	Insider Own	0.40%	Shs Outstand	137.12M	Perf Week	-2.89%
Market Cap	3.34B	Forward P/E	-	EPS next Y	-1.31	Insider Trans	-33.88%	Shs Float	135.81M	Perf Month	8.66%
Income	-185.20M	PEG	-	EPS next Q	-0.46	Inst Own	96.20%	Short Float / Ratio	7.42% / 4.16	Perf Quarter	6.85%
Sales	-	P/S	-	EPS this Y	-36.10%	Inst Trans	4.74%	Short Interest	10.08M	Perf Half Y	36.99%
Book/sh	4.26	P/B	5.59	EPS next Y	-4.20%	ROA	-44.30%	Target Price	31.17	Perf Year	42.30%
Cash/sh	4.61	P/C	5.17	EPS next 5Y	-	ROE	-52.20%	52W Range	8.85 - 26.35	Perf YTD	11.40%
Dividend	-	P/FCF	-	EPS past 5Y	-19.90%	ROI	-	52W High	-9.49%	Beta	1.09
Dividend %	-	Quick Ratio	18.60	Sales past 5Y	-	Gross Margin	-	52W Low	169.49%	ATR	1.32
Employees	74	Current Ratio	18.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	56.28	Volatility	4.97% 7.40%
Optionable	Yes	Debt/Eq	0.18	EPS Q/Q	-64.50%	Profit Margin	-	Rel Volume	0.45	Prev Close	23.81
Shortable	Yes	LT Debt/Eq	0.18	Earnings	Mar 01 BMO	Payout	-	Avg Volume	2.42M	Price	23.85
Recom	1.70	SMA20	5.90%	SMA50	10.12%	SMA200	35.19%	Volume	160,717	Change	0.17%

Nov-10-22

Downgrade

Jefferies

Buy → Hold

$30 → $20

Oct-17-22

Upgrade

B. Riley Securities

Sell → Neutral

Sep-06-22

Downgrade

B. Riley Securities

Neutral → Sell

$12 → $8

Aug-02-22

Initiated

UBS

Buy

$20

Jun-08-22

Initiated

Guggenheim

Buy

$30

Jun-08-22

Initiated

BofA Securities

Buy

$18

May-12-22

Initiated

B. Riley Securities

Neutral

$12

Mar-22-22

Initiated

Jefferies

Buy

$27

Mar-03-22

Initiated

Robert W. Baird

Outperform

$27

Feb-07-22

Initiated

Morgan Stanley

Overweight

$25

Show Previous Ratings

Mar-03-23 10:57AM	IVERIC bio, Inc. (NASDAQ:ISEE) Q4 2022 Earnings Call Transcript Insider Monkey
Mar-02-23 04:15PM	Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Mar-01-23 11:52PM	Q4 2022 IVERIC bio Inc Earnings Call Thomson Reuters StreetEvents +16.94%
03:30PM	IVERIC Bio (ISEE) Q4 2022 Earnings Call Transcript Motley Fool
12:40PM	IVERIC bio's Geographic Atrophy Candidate Shows Significant Reduction In Disease Progression Benzinga
06:32AM	Loading…
06:32AM	Iveric Bio Reports Fourth Quarter and Full Year 2022 Operational Highlights and Financial Results Business Wire
06:30AM	Iveric Bio Announces Vision Loss Reduction Data in Geographic Atrophy from Avacincaptad Pegol GATHER Trials Business Wire
Feb-28-23 08:00AM	Iveric Bio to Present at the Cowen 43rd Annual Health Care Conference Business Wire
Feb-22-23 08:00AM	Iveric Bio to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on Wednesday, March 1, 2023 Business Wire
Feb-21-23 04:05PM	Apellis Surges To Four-Month High Sending Rival Iveric Tumbling On A First-Ever Approval Investor's Business Daily -13.62%
Feb-16-23 04:01PM	Iveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic Atrophy Business Wire
Feb-02-23 04:01PM	Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-24-23 10:20AM	Insiders who bought IVERIC bio, Inc. (NASDAQ:ISEE) last year must be regretting not buying more as market cap hits US$2.8b Simply Wall St.
Jan-04-23 08:00AM	Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-03-23 02:42PM	RTP gene therapy startup expands pipeline through deal with public biotech American City Business Journals -6.03%
07:30AM	Loading…
07:30AM	Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors Business Wire
Dec-20-22 07:30AM	Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy Business Wire
Dec-02-22 08:00AM	Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-30-22 11:38PM	Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock Business Wire
04:01PM	Iveric Bio Announces Proposed Offering of Common Stock Business Wire
Nov-18-22 06:58AM	IVERIC bio Secures Breakthrough Therapy Tag For Its Flagship Geographic Atrophy Candidate Benzinga +25.58%
Nov-17-22 04:01PM	Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy Business Wire
Nov-04-22 04:30PM	Iveric Bio to Present at Upcoming Investor Conferences Business Wire -11.08%
04:24PM	Apellis Pharma Crashes On Unexpected Delay For Eye Drug, Taking A Key Rival With It Investor's Business Daily
Nov-03-22 10:01PM	IVERIC bio, Inc. (ISEE) Q3 2022 Earnings Call Transcript Motley Fool
06:30PM	Iveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy Business Wire
06:30AM	Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results Business Wire
Nov-02-22 08:00AM	Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Oct-27-22 08:00AM	Iveric Bio to Report Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 3, 2022 Business Wire
Oct-04-22 08:00AM	Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +8.32%
08:00AM	Loading…
Sep-27-22 08:00AM	Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting Business Wire
Sep-08-22 04:23PM	Why Iveric Bio Stock Is Skyrocketing This Week Motley Fool +18.34%
Sep-07-22 01:31PM	IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study Zacks
08:00AM	Iveric Bio to Present at Upcoming Investor Conferences Business Wire
Sep-06-22 09:45AM	The 2 Stocks Everyone's Talking About Tuesday Motley Fool +66.31%
07:51AM	IVERIC bio Stock Soars After Encouraging Geographic Atrophy Trial Data Benzinga
06:00AM	Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy Business Wire
Sep-02-22 08:00AM	Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-10-22 08:00AM	Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference Business Wire
Aug-03-22 04:42PM	7 Cheap Biotech Stocks to Buy Now InvestorPlace
08:00AM	Iveric Bio to Present at the Wedbush PacGrow Healthcare Conference 2022 Business Wire
Aug-02-22 08:00AM	Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jul-26-22 12:00PM	IVERIC bio, Inc. (ISEE) Q2 2022 Earnings Call Transcript Motley Fool
08:08AM	IVERIC bio Shares Jump On Debt Financing To Fund Zimura Launch Benzinga
06:32AM	Iveric Bio Reports Second Quarter 2022 Operational Highlights and Financial Results Business Wire
06:30AM	Iveric Bio Announces Agreement for Up to $250 Million in Non-Dilutive Debt Financing with Hercules Capital and Silicon Valley Bank Business Wire
Jul-21-22 04:18PM	Iveric Bio to Report Second Quarter 2022 Financial Results and Host Conference Call on Tuesday, July 26, 2022 Business Wire
Jul-16-22 11:15AM	Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® at American Society of Retina Specialists Meeting Business Wire
Jul-12-22 06:55PM	Morgan Stanley: Despite Turbulent Economy, These Stocks Have Over 90% Upside Potential TipRanks
Jul-05-22 07:30AM	Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura® Business Wire +7.98%
Jul-01-22 04:52PM	Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jun-10-22 07:00AM	Iveric Bio Announces Presentation of Post-Hoc Analysis at Macula Society from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy Business Wire -7.06%
Jun-08-22 07:08AM	IVERIC bio, Inc. (NASDAQ:ISEE) insiders are still down US$16k after purchasing last year, recent gain helped regain some losses Simply Wall St.
Jun-02-22 08:00AM	Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-17-22 08:00AM	Iveric Bio to Present at the UBS Global Healthcare Conference 2022 Business Wire +6.81%
May-16-22 08:00AM	Iveric Bio to Participate in the H.C. Wainwright Global Investment Conference Business Wire
May-04-22 01:00PM	IVERIC bio, Inc. (ISEE) Q1 2022 Earnings Call Transcript Motley Fool
06:32AM	Iveric Bio Reports First Quarter 2022 Operational Highlights and Financial Results Business Wire
06:30AM	Iveric Bio Announces Presentation of Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy Business Wire
May-03-22 08:00AM	Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Apr-27-22 08:00AM	Iveric Bio to Report First Quarter 2022 Financial Results and Host Conference Call on Wednesday, May 4, 2022 Business Wire
Apr-26-22 08:00AM	Iveric Bio to Participate in the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference Business Wire -7.41%
Apr-01-22 08:04PM	Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation Simply Wall St. +5.70%
06:41PM	Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
05:13AM	Top Biotech Stocks for Q2 2022 Investopedia
Mar-02-22 08:00AM	Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-28-22 08:00AM	Iveric Bio to Present at the Cowen 42nd Annual Health Care Conference Business Wire
Feb-24-22 06:00PM	IVERIC bio, Inc. (ISEE) Q4 2021 Earnings Call Transcript Motley Fool +7.34%
06:30AM	Iveric Bio Reports Fourth Quarter and Full Year 2021 Operational Highlights and Financial Results Business Wire
Feb-17-22 08:00AM	Iveric Bio to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022 Business Wire
02:38AM	Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs Samsara BioCapital Insider Monkey
Feb-11-22 08:00AM	Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy Business Wire
Feb-07-22 08:00AM	Iveric Bio Announces New Post-Hoc Analyses of Zimura® from GATHER1 Clinical Trial to Be Presented at Angiogenesis, Exudation, and Degeneration 2022 Business Wire +7.99%
Feb-05-22 03:07PM	Were Hedge Funds Right About IVERIC bio, Inc. (ISEE)? Insider Monkey
Feb-02-22 08:00AM	Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-06-22 08:00AM	Iveric Bio Announces the Addition of Global Pharmaceutical Veteran, Christine Ann Miller, to its Board of Directors Business Wire
Jan-04-22 04:35PM	Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire -9.35%
08:00AM	Iveric Bio to Present at the H.C. Wainwright BioConnect Virtual Conference Business Wire
Dec-30-21 07:06AM	IVERIC bio, Inc. (NASDAQ:ISEE) insider upped their holding by 77% earlier this year Simply Wall St.
Dec-28-21 09:19AM	BridgeBio (BBIO) Tumbles on Cardiomyopathy Candidate Failure Zacks
09:15AM	Iveric Bio Inc (ISEE) CEO Glenn Sblendorio Sold $980,058 of Shares GuruFocus.com
Dec-23-21 11:15PM	Iveric Bio Inc (ISEE) SVP, CFO and Treasurer David Francis Carroll Sold $898,188 of Shares GuruFocus.com
08:50AM	IVERIC bio (ISEE) is on the Move, Here's Why the Trend Could be Sustainable Zacks
Dec-21-21 12:18PM	Glaxo (GSK) Gets FDA Nod for HIV Preventive Injectable Drug Zacks
Dec-20-21 10:31AM	bluebird's (BLUE) BLA for CALD Therapy Gets Priority Review Zacks
10:20AM	Novavax (NVAX) COVID Jab Gets WHO Nod for Emergency Use Listing Zacks
Dec-17-21 09:44AM	Biogen (BIIB) to Begin Aduhelm Confirmatory Study in 2022 Zacks
Dec-16-21 10:26AM	Jazz (JAZZ) Enrols First Patient in Essential Tremor Study Zacks
Dec-14-21 05:19PM	Bellus (BLU) Stock Surges on Data From Chronic Cough Study Zacks
05:17PM	Intellia (NTLA) Begins Dosing in Hereditary Angioedema Study Zacks
Dec-13-21 05:08PM	Iveric Bio Appoints Tony Gibney as Executive Vice President and Chief Business and Strategy Officer Business Wire
Dec-09-21 11:18AM	Reata (RETA) Falls on Negative Advisory Committee Outcome Zacks
10:38AM	Affimed (AFMD) Starts AFM24-102 Study With Roche's Tecentriq Zacks
Dec-08-21 11:14AM	Hedge Funds Are Crazy About IVERIC bio, Inc. (ISEE) Insider Monkey
Dec-07-21 10:26AM	Reata (RETA) Plunges on FDA Concerns for Kidney Failure Drug Zacks
Dec-03-21 11:58AM	7 A-Rated Biotechs to Buy for the Long Run InvestorPlace -5.11%
Dec-02-21 10:13AM	Vertex (VRTX) Up on Kidney Disease Drug's Success in Phase II Zacks +5.24%
08:00AM	Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Dec-01-21 01:52PM	AbbVie (ABBV) Files for Skyrizi to Treat Crohn's Disease in EU Zacks
01:38PM	Jazz (JAZZ) Begins Zepzelca Combo Study for First-Line SCLC Zacks

IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Westby Keith	SVP, Chief Operating Officer	Mar 02	Option Exercise	1.45	13,298	19,282	59,652	Mar 06 04:34 PM
Westby Keith	SVP, Chief Operating Officer	Mar 02	Sale	23.93	20,000	478,614	39,652	Mar 06 04:34 PM
Westby Keith	SVP, Chief Operating Officer	Feb 17	Option Exercise	4.12	15,000	61,818	57,568	Feb 22 05:52 PM
Westby Keith	SVP, Chief Operating Officer	Feb 17	Sale	25.05	15,000	375,750	46,354	Feb 22 05:52 PM
Westby Keith	SVP, Chief Operating Officer	Feb 02	Sale	23.82	20,000	476,400	46,354	Feb 03 04:26 PM
Westby Keith	SVP, Chief Operating Officer	Feb 01	Sale	23.03	20,000	460,600	66,354	Feb 03 04:26 PM
SBLENDORIO GLENN	Chief Executive Officer	Jan 03	Sale	20.06	17,447	349,987	228,191	Jan 04 06:34 PM
Carroll David Francis	SVP, Chief Financial Officer	Jan 03	Sale	20.06	3,602	72,256	68,472	Jan 04 06:33 PM
Westby Keith	SVP, Chief Operating Officer	Jan 03	Sale	20.06	3,480	69,809	86,354	Jan 04 06:34 PM
Simms Christopher Paul	SVP, Chief Commercial Officer	Jan 03	Sale	20.06	2,368	47,502	32,429	Jan 04 06:33 PM
Westby Keith	SVP, Chief Operating Officer	Jan 02	Option Exercise	0.00	8,750	0	89,834	Jan 04 06:34 PM
Simms Christopher Paul	SVP, Chief Commercial Officer	Jan 02	Option Exercise	0.00	6,250	0	34,797	Jan 04 06:33 PM
Carroll David Francis	SVP, Chief Financial Officer	Jan 02	Option Exercise	0.00	8,750	0	72,074	Jan 04 06:33 PM
SBLENDORIO GLENN	Chief Executive Officer	Jan 02	Option Exercise	0.00	31,500	0	245,638	Jan 04 06:34 PM
Dugel Pravin	President	Jan 02	Option Exercise	0.00	12,500	0	148,723	Jan 04 06:35 PM
SBLENDORIO GLENN	CEO	Dec 19	Sale	21.51	19,457	418,520	244,138	Dec 20 07:02 PM
Westby Keith	SVP & COO	Dec 19	Sale	21.51	6,740	144,977	81,084	Dec 20 07:02 PM
Carroll David Francis	CFO	Dec 19	Sale	21.51	5,671	121,983	63,324	Dec 20 07:01 PM
SBLENDORIO GLENN	CEO	Dec 18	Option Exercise	0.00	36,658	0	263,595	Dec 20 07:02 PM
Westby Keith	SVP & COO	Dec 18	Option Exercise	0.00	12,500	0	87,824	Dec 20 07:02 PM
Dugel Pravin	President	Dec 18	Option Exercise	0.00	13,750	0	136,223	Dec 20 07:00 PM
Carroll David Francis	CFO	Dec 18	Option Exercise	0.00	14,375	0	68,995	Dec 20 07:01 PM
Gibney Anthony S	EVP, Chief Business Officer	Dec 13	Option Exercise	0.00	31,000	0	42,791	Dec 14 04:28 PM
Westby Keith	SVP & COO	Dec 13	Sale	21.73	6,741	146,482	75,324	Dec 13 09:02 PM
Carroll David Francis	CFO	Dec 13	Sale	21.73	4,932	107,172	54,620	Dec 13 09:01 PM
Carroll David Francis	CFO	Dec 12	Option Exercise	0.00	12,500	0	59,552	Dec 13 09:01 PM
SBLENDORIO GLENN	CEO	Dec 12	Option Exercise	0.00	22,950	0	226,937	Dec 13 09:01 PM
Westby Keith	SVP & COO	Dec 12	Option Exercise	0.00	12,500	0	82,065	Dec 13 09:02 PM
Westby Keith	SVP & COO	Dec 12	Sale	20.89	5,393	112,662	69,565	Dec 13 09:02 PM
Carroll David Francis	CFO	Dec 12	Sale	20.89	3,946	82,434	47,052	Dec 13 09:01 PM
Westby Keith	SVP & COO	Dec 09	Option Exercise	0.00	10,000	0	74,958	Dec 13 09:02 PM
SBLENDORIO GLENN	CEO	Dec 09	Option Exercise	0.00	23,750	0	203,987	Dec 13 09:01 PM
Carroll David Francis	CFO	Dec 09	Option Exercise	0.00	10,000	0	50,998	Dec 13 09:01 PM
Westby Keith	SVP & COO	Dec 02	Option Exercise	10.03	5,199	52,146	64,958	Dec 05 05:37 PM
Westby Keith	SVP & COO	Dec 01	Sale	22.96	10,030	230,289	59,759	Dec 05 05:37 PM
Dugel Pravin	President	Nov 17	Option Exercise	10.03	8,474	84,994	122,473	Nov 21 07:48 PM
SBLENDORIO GLENN	CEO	Nov 02	Sale	23.01	50,000	1,150,500	179,689	Nov 04 05:01 PM
Westby Keith	SVP & COO	Nov 01	Option Exercise	1.45	42,916	62,228	142,044	Nov 03 08:00 PM
Westby Keith	SVP & COO	Nov 01	Sale	23.92	72,916	1,744,151	69,128	Nov 03 08:00 PM
Simms Christopher Paul	SVP, Chief Commercial Officer	Aug 03	Sale	11.25	12,272	138,060	28,547	Aug 04 04:09 PM
Simms Christopher Paul	SVP, Chief Commercial Officer	Aug 02	Option Exercise	0.00	33,750	0	40,819	Aug 04 04:09 PM
Blumenkranz Mark S.	Director	Jul 15	Option Exercise	0.00	5,000	0	17,500	Jul 19 04:09 PM
Gibney Anthony S	EVP, Chief Business Officer	Jul 05	Sale	9.41	7,791	73,313	10,959	Jul 05 06:30 PM
Gibney Anthony S	EVP, Chief Business Officer	Jun 30	Option Exercise	0.00	18,750	0	18,750	Jul 05 06:30 PM
Roberts Calvin W.	Director	Jun 13	Buy	9.62	25,000	240,500	32,500	Jun 14 04:55 PM
Dugel Pravin	President	May 03	Option Exercise	0.00	4,313	0	113,999	May 05 06:02 PM
Westby Keith	SVP & COO	Apr 18	Sale	16.63	10,000	166,300	99,128	Apr 20 04:51 PM
Westby Keith	SVP & COO	Apr 05	Option Exercise	1.45	9,298	13,482	118,426	Apr 06 06:13 PM
Carroll David Francis	CFO	Apr 05	Option Exercise	1.45	4,684	6,792	44,850	Apr 05 06:25 PM
Westby Keith	SVP & COO	Apr 05	Sale	19.02	9,298	176,808	109,128	Apr 06 06:13 PM
Carroll David Francis	CFO	Apr 05	Sale	19.01	4,684	89,043	40,166	Apr 05 06:25 PM
Westby Keith	SVP & COO	Apr 04	Option Exercise	1.45	20,702	30,018	129,830	Apr 06 06:13 PM
Carroll David Francis	CFO	Apr 04	Option Exercise	1.45	20,316	29,458	81,107	Apr 05 06:25 PM
SBLENDORIO GLENN	CEO	Apr 04	Sale	18.76	50,000	937,805	229,689	Apr 06 06:11 PM
Carroll David Francis	CFO	Apr 04	Sale	18.50	40,941	757,311	40,166	Apr 05 06:25 PM
Westby Keith	SVP & COO	Apr 04	Sale	19.00	20,702	393,346	109,128	Apr 06 06:13 PM
SBLENDORIO GLENN	CEO	Apr 01	Option Exercise	2.94	40,756	119,823	320,445	Apr 01 07:03 PM
SBLENDORIO GLENN	CEO	Apr 01	Sale	17.50	40,756	713,230	279,689	Apr 01 07:03 PM
Carroll David Francis	CFO	Apr 01	Sale	17.00	2,144	36,448	60,791	Apr 05 06:25 PM
SBLENDORIO GLENN	CEO	Mar 31	Option Exercise	2.94	1,400	4,116	281,089	Apr 01 07:03 PM
SBLENDORIO GLENN	CEO	Mar 31	Sale	17.02	1,400	23,828	279,689	Apr 01 07:03 PM
SBLENDORIO GLENN	CEO	Mar 30	Option Exercise	2.94	1,213	3,566	280,902	Apr 01 07:03 PM
SBLENDORIO GLENN	CEO	Mar 30	Sale	17.00	1,213	20,626	279,689	Apr 01 07:03 PM
SBLENDORIO GLENN	CEO	Mar 25	Option Exercise	2.94	18,775	55,198	298,464	Mar 29 07:44 PM
Carroll David Francis	CFO	Mar 25	Option Exercise	1.45	16,763	24,306	79,707	Mar 29 07:45 PM
SBLENDORIO GLENN	CEO	Mar 25	Sale	17.06	18,775	320,302	279,689	Mar 29 07:44 PM
Carroll David Francis	CFO	Mar 25	Sale	17.02	16,772	285,387	62,935	Mar 29 07:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience